Down 65% in 2024, but can the Avacta (AVCT) share price ever recover?

Some investors have done well in the life sciences sector, so does AVCT have potential now the share price has fallen so far?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Avacta‘s (LSE: AVCT) a clinical-stage life sciences company, and it caught the attention of investors when the share price shot up in 2020. The big hope is that it will rocket higher again someday.

Back then in the pandemic, the business developed products used for Covid-19 testing. It even managed to sell some of them. That created speculative buying for the stock.

However, even the firm’s Covid test kits weren’t enough to create overall profits for the enterprise.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Getting out of diagnostics

In September, the firm said it’s looking for a buyer for its diagnostics division. If successful, it could gain some much-needed capital. But at the same time it will kill off the revenue stream from that division.

Meanwhile, the share price chart mirrors the changing fortunes of the company. With the stock in the ballpark of 45p, it’s down around 65% this year.

Created with Highcharts 11.4.3Avacta Group Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

The main ongoing focus of Avacta’s efforts is the development of cancer therapies. The company describes its pre|CISION technology as a “proprietary warhead delivery system”.

Operational progress

Given the large number of cancer sufferers, a war on the disease seems like an attractive proposition. Avacta’s trying to develop treatments to target the tumours themselves, while sparing harmful effects on normal tissues. Perhaps that area of operations can produce a future top-selling product and relaunch the share price.

The company delivered an update on progress with September’s interim results report. Chairman Shaun Chilton said the firm’s prioritising further investments in therapeutics, including the “acceleration” of its AVA6000 clinical trial enrolment.

AVA6000 showed a “highly encouraging” tolerability profile with “robust” initial efficacy signals in both dose-escalation arms of its Phase 1a trial.

The directors are “encouraged” by the potential of the “innovative” medicines in the Avacta pipeline. The firm’s AVA6000, AVA6103, and AVA7100 programmes are “highly differentiated pipeline assets, addressing large markets”

Big costs, small revenues

Nevertheless, early-stage development’s an expensive and cash-consuming game. Loss-making companies like this tend to keep operations going by issuing more shares and raising extra money from shareholders. For example, Avacta did a fundraise in March to raise just over £31m.

Every issue of new shares dilutes existing holders. So if a drug development phase lasts too long, there can sometimes be little benefit left for the longest and most patient investors. That’s even if the business does eventually start earning decent money.

On top of that, treatments can fail even in the later stages of development. So those uncertainties are the biggest risks for Avacta shareholders today.

Nevertheless, the company’s been progressing its stable of potential new treatments and every passing week may take it closer to commercial success. So Avacta shares could recover at some point. But there’s a lot of risk for shareholders to carry in the meantime.

This AI stock is becoming a digital juggernaut in a £ 12.5 billion market!

🤖 Curious about the next big player in AI? 🤖

Our leading industry analysts have uncovered a trailblazing content platform that's revolutionising the industry with its unparalleled generative AI technology, setting new standards in creativity and efficiency.

Care for a sneak peek?

Trusted by global giants like Amazon, Disney, and Netflix, this innovative company is not just transforming digital media with AI-generated 3D content but is also capturing a significant share of a £12.7 billion market!

With a remarkable 62% gross margin, indicating exceptional profitability and operational efficiency, this company's growth trajectory positions it as a must-watch for savvy investors.

Best of all, we're offering exclusive access to the name of this game-changing stock, absolutely free!

Discover your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Forget Lloyds’ cheap share price! I’d rather consider this FTSE 100 bargain share

Lloyds' share price might appear too cheap to miss at first glance. But this FTSE-listed share could be a better…

Read more »

Market Movers

Down 6% today, is the BT share price gearing up for a larger fall?

Jon Smith points out why the BT share price has tumbled today, but flags up why the reasoning behind the…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

This FTSE 100 stock is down 25% from its 52-week high. Should I buy?

Analysts think the price-to-earnings ratio of this FTSE 100 stock could fall by half in the next two years if…

Read more »

Investing Articles

£10,000 invested in Nvidia stock just two weeks ago is already worth…

Nvidia stock's been making big losses and big gains so far in 2025, at least on paper. But long-term valuation…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Here’s why Lloyds shares have dipped sharply

Lloyds shares got a boost recently when the Treasury petitoned the Supreme Court to go easy on the car loan…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

A £10,000 investment in BAE Systems shares 5 years ago is now worth…

BAE Systems' shares have lifted off since the start of the decade. But can the FTSE 100 defence giant continue…

Read more »

Dividend Shares

£8,000 invested in high-yield dividend stocks could make this amount of passive income

Jon Smith explains how dividend shares with yields in excess of 8% can be used carefully in order to build…

Read more »

Investing Articles

£5,000 invested in Tesco shares 2 years ago is now worth…

Over the last two years, Tesco shares have provided investors with gains of around 30% per year when dividends are…

Read more »